Fucun Xie
Overview
Explore the profile of Fucun Xie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
510
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bai Y, Zhang H, Lin Z, Huang S, Xie F, Gao S, et al.
Cell Signal
. 2025 Feb;
129:111671.
PMID: 39971224
Hepatocellular carcinoma (HCC) is one of leading causes of cancer-related death and new approaches are urgently needed, given current dearth of therapies. Long non-coding RNAs (lncRNAs) have been linked to...
2.
Chen P, Long J, Zhang J, Xie F, Wu W, Tian Z, et al.
Inflamm Res
. 2024 Jan;
73(2):263-276.
PMID: 38200372
Background: Janus kinase 2 (JAK2) mutation plays an important role in T cell immunity. However, the effect of JAK2 mutation on immunotherapy is largely uncharacterized. Methods: In this study, we...
3.
Bai Y, Xu J, Li D, Zhang X, Chen D, Xie F, et al.
Clin Epigenetics
. 2023 Jun;
15(1):99.
PMID: 37308980
Background: Early screening and detection of hepatocellular carcinoma (HCC) can efficiently improve patient prognosis. We aimed to identify a series of hypermethylated DNA markers and develop a blood-based HCC diagnosis...
4.
Yang X, Chen B, Wang Y, Wang Y, Long J, Zhang N, et al.
Hepatol Int
. 2023 Feb;
17(3):709-719.
PMID: 36753026
Introduction: Combining lenvatinib with a programmed cell death protein-1 (PD-1) inhibitor has been explored for the treatment of un-resectable hepatocellular carcinoma (uHCC). This study aimed to investigate the real-world efficacy...
5.
Xie F, Chen B, Yang X, Wang H, Zhang G, Wang Y, et al.
Front Immunol
. 2022 Dec;
13:1052937.
PMID: 36569829
Background: Lenvatinib is a standard first-line systemic therapy in advanced hepatocellular carcinoma (aHCC) and is widely used in all lines. However, the efficacy and safety of immune checkpoint inhibitors (ICIs)...
6.
Liao W, Long J, Li Y, Xie F, Xun Z, Wang Y, et al.
Front Cell Dev Biol
. 2022 Aug;
10:910749.
PMID: 35912098
N6-methyladenosine (m6A) and lncRNAs have been implicated in the development of colon cancer, including tumorigenesis, migration, and invasion. However, the specific effect of m6A regulators on lncRNAs is not clear,...
7.
Xie F, Wang H, Zhang G, Yang X, Zhao H
HPB (Oxford)
. 2022 Jul;
24(10):1816-1817.
PMID: 35872124
No abstract available.
8.
Wang Z, Wu Y, Huang J, Xie F, Gong L, Li S
Surg Today
. 2022 May;
52(9):1358-1372.
PMID: 35522343
Background And Purpose: The wide application of low-dose computed tomography (CT) has led to an increase in the detection of small lung cancer lesions. Moreover, surgical recommendations for second primary...
9.
Mao J, Wang D, Long J, Yang X, Lin J, Song Y, et al.
J Immunother Cancer
. 2021 Dec;
9(12).
PMID: 34873013
Background: The gut microbiome is associated with the response to immunotherapy for different cancers. However, the impact of the gut microbiome on hepatobiliary cancers receiving immunotherapy remains unknown. This study...
10.
Wang Z, Xie F, Wu Y, Wang L, Bai Y, Long J, et al.
Int Immunopharmacol
. 2021 Nov;
101(Pt B):108376.
PMID: 34815191
High incidence of recurrency had been a significant threat among glioma patients. Moreover, the performance of traditional therapies among recurrent gliomas was far from satisfying. Advances in the tumor microenvironment...